Radioligand therapy for HER2-positive cancers enters human trials for the first time

Medical Xpress

Radioligand therapy for HER2-positive cancers enters human trials for the first time

이 뉴스, 어떠셨어요?

한 번의 탭으로 반응을 남겨요 · 로그인 불필요

The McGill University Health Centre (MUHC) is the first site in the world to launch a first-in-human phase 1 clinical trial evaluating a novel radioligand therapy for HER2-positive cancers, including certain types of breast cancer. ...

전문 보기

Radioligand therapy for HER2-positive cancers enters human trials for the first time

이 뉴스, 어떠셨어요?

관련 뉴스

'science' 카테고리 뉴스

Heat-struck Italians cool off in ancient stone 'trulli'

Hybrid reef project off Miami Beach targets wave attenuation and coral recovery

Language models read doctors' notes to reveal why patients discontinue medication

Medical Xpress의 다른 기사

Use of supplement before surgery may improve liver regeneration

Not everyone has equal access to pain rehabilitation

Developing a new methodology to identify biomarkers for male infertility